Amgen (NASDAQ:AMGN – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Amgen to similar companies based on the strength of its profitability, institutional ownership, valuation, dividends, risk, earnings and analyst recommendations.
Profitability
This table compares Amgen and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amgen | 24.14% | 114.99% | 13.47% |
| Amgen Competitors | -12,516.26% | -215.91% | -31.70% |
Risk and Volatility
Amgen has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Amgen’s rivals have a beta of -1.85, suggesting that their average stock price is 285% less volatile than the S&P 500.
Insider and Institutional Ownership
76.5% of Amgen shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Amgen and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Amgen | $38.90 billion | $7.71 billion | 25.47 |
| Amgen Competitors | $757.61 million | $11.26 million | -18.37 |
Amgen has higher revenue and earnings than its rivals. Amgen is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a summary of current ratings and price targets for Amgen and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amgen | 3 | 18 | 11 | 1 | 2.30 |
| Amgen Competitors | 9920 | 15335 | 45741 | 1601 | 2.54 |
Amgen currently has a consensus price target of $428.62, suggesting a potential downside of 2.40%. As a group, “Biotechnology” companies have a potential upside of 113.73%. Given Amgen’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Amgen has less favorable growth aspects than its rivals.
Dividends
Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.3%. Amgen pays out 58.5% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 1.6% and pay out 71.0% of their earnings in the form of a dividend. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.
Summary
Amgen beats its rivals on 11 of the 15 factors compared.
Amgen Company Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
